Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04762446
Other study ID # 294270
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 15, 2022
Est. completion date November 30, 2023

Study information

Verified date April 2024
Source Barts & The London NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Surgical site infections (SSI) are serious complications accounting for 20% of all the healthcare-associated infections and are considered the second most frequent type of hospital-acquired infection in Europe and the United States. SSI after cardiac surgery is associated with delays to patient's discharge, readmissions and re-operations; and can result in increased hospital costs for staffing, diagnostics and treatment. Risk assessment has been identified as potentially useful intervention in SSI prevention and in identifying at risk populations who may benefit from specific interventions to reduce this possible complication of cardiac surgery. However, there is currently a lack of evidence as to which risk tools are the most valid and reliable to be used in clinical practice. The investigators developed and locally validated the Barts Heart Centre Surgical Infection Risk (B-SIR) tool to include patients with various types of cardiac surgeries and found that the B-SIR tool is a better tool in predicting SSI risk compared with the existing cardiac risk tools in the study population. However, various literatures recognised that the predictive performance of a risk model tends to vary across settings, populations and periods. Hence, the investigators aim to do a multi-centre validation of the newly developed B-SIR tool and apply all the other tools (Australian Cardiac Risk Index and Brompton and Harefield Infection Score) to identify what tool performs best that can potentially be use for the UK population. Further, the outcome of the study will be beneficial to future cardiac surgery patients to assess their risk of developing SSI and help identify those patients who may benefit from specific interventions. Existing patients' data, which will be anonymised, from the participating cardiac centres will be utilised to analyse and compare the performance of each risk tools.


Description:

Surgical site infections (SSI) are serious complications accounting for 20% of all the healthcare-associated infections and are considered the second most frequent type of hospital-acquired infection in Europe and the United States. The incidence of SSI in England at 30-days is 8.6% for coronary artery bypass graft (CABG) and 2.2% for non-CABG operations. SSI after cardiac surgery is associated with delays to patient's discharge, readmissions and re-operations; and can result in increased hospital costs for staffing, diagnostics and treatment. Risk assessment has been identified as potentially useful intervention in SSI prevention and in identifying at risk populations who may benefit from targeted interventions to reduce this possible complication of cardiac surgery. However, there is currently a lack of evidence as to which risk tools are the most valid and reliable to be used in clinical practice. The investigators developed and locally validated the Barts Heart Centre Surgical Infection Risk (B-SIR) tool to include patients with various types of cardiac surgeries and found that the B-SIR tool has a greater predictive power of SSI risk compared with the existing cardiac risk tools in the study population. However, various literatures recognised that the predictive performance of a risk model tends to vary across settings, populations and periods. Verification of the robustness and generalisability of a developed model is highly recommended in one or more external validation studies. Hence, the investigators aim to do a multi-centre validation of the newly developed B-SIR tool and apply all the other tools (Australian Cardiac Risk Index and Brompton and Harefield Infection Score) to identify what tool performs best that can potentially be use for the UK population. This study is a secondary data analysis that will utilise prospectively collected data that were locally collected in 6 UK cardiac centres for the National Institute for Cardiovascular Outcome Research (NICOR) and Public Health of England (PHE) Surgical Site Infection Surveillance. Data on various patients' risk factors will be collected and analysed to compare the ability of each risk assessment tool in predicting SSI after cardiac surgery. The outcome of this study will be beneficial to future cardiac surgery patients to assess their risk of developing SSI and help identify those patients who may benefit from targeted interventions.


Recruitment information / eligibility

Status Completed
Enrollment 6379
Est. completion date November 30, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria: 1. >/= 18 years old at the time of surgery; and 2. had a primary surgery (CABG, valve surgery or both) in the UK cardiac centres. Exclusion Criteria: 1. patients undergoing grown-up congenital heart disease related surgery; 2. patients with concurrent aortovascular surgery; 3. patients who had ventricular-assist device (VAD), haemolung, impellar and/or extracorporeal membrane oxygenator (ECMO) before and/or after cardiac surgery; 4. patients who had an open-chest immediately after surgery.

Study Design


Locations

Country Name City State
United Kingdom Liverpool Heart and Chest Hospital Liverpool
United Kingdom James Cook University Hospital Middlesbrough
United Kingdom Oxford University Hospital Oxford

Sponsors (7)

Lead Sponsor Collaborator
Barts & The London NHS Trust Belfast Health and Social Care Trust, Cardiff and Vale University Health Board, Liverpool Heart and Chest Hospital NHS Foundation Trust, Oxford University Hospitals NHS Trust, South Tees Hospitals NHS Foundation Trust, University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

References & Publications (8)

Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, Moons KG. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol. 2003 Sep;56(9):826-32. doi: 10.1016/s0895-4356(03)00207-5. — View Citation

Debray TP, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KG. A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015 Mar;68(3):279-89. doi: 10.1016/j.jclinepi.2014.06.018. Epub 2014 Aug 30. — View Citation

Lamagni T CK, Wloch C, Harrington P. The epidemiology of cardiac surgical site infection in Englad, 2018/19. 30th European Congress of Clinical Microbiology and Infectious Diseases. 2020; Paris, France: Clin Microbiol Infect 2020.

Magboo R, Drey N, Cooper J, Byers H, Shipolini A, Sanders J. Predicting cardiac surgical site infection: development and validation of the Barts Surgical Infection Risk tool. J Clin Epidemiol. 2020 Dec;128:57-65. doi: 10.1016/j.jclinepi.2020.08.015. Epub 2020 Aug 25. — View Citation

Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM; Emerging Risk Factors Collaboration. Assessing risk prediction models using individual participant data from multiple studies. Am J Epidemiol. 2014 Mar 1;179(5):621-32. doi: 10.1093/aje/kwt298. Epub 2013 Dec 22. — View Citation

Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med. 2004 Mar 30;23(6):907-26. doi: 10.1002/sim.1691. — View Citation

Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, Riley RD, Hemingway H, Altman DG; PROGRESS Group. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2):e1001381. doi: 10.1371/journal.pmed.1001381. Epub 2013 Feb 5. — View Citation

Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010 Oct 15;172(8):971-80. doi: 10.1093/aje/kwq223. Epub 2010 Aug 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Predictive power of the risk tools The primary outcome will be the assessment and comparison of the predictive power of B-SIR, ACRI and BHIS tools. The predictive power of each risk tool will be determined using the area under the curve (AUC) from receiver operating characteristic (ROC) curve. AUC can be between 0.5 - 1; higher score (closer to 1) indicates greater predictive ability. January 2018 - December 2019
Secondary Calibration scores of the risk tools The secondary outcome will be the assessment and comparison of the calibration of scores of B-SIR, ACRI and BHIS tools. Hosmer-Lemeshow goodness of fit test will be utilised to determine calibration of scores. This will be done to examine the ability of each model to generate predictions that are on average close to the average observed outcome. For this test, a p-value that is not statistically significant (p > 0.05) will be considered to indicate a reasonable model fit. January 2018 - December 2019
See also
  Status Clinical Trial Phase
Recruiting NCT05054179 - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain Phase 2/Phase 3
Completed NCT04051021 - Non-Pharmacological Interventions on Patient Experience and Healthcare Utilization in Adult Cardiac Surgery Patients N/A
Recruiting NCT04604886 - The Consistency of Cardiac Output Measured by Pulmonary Artery Catheter and LiDCO in Cardiac Surgical Patients N/A
Recruiting NCT04075981 - Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) Phase 3
Completed NCT04062396 - Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction N/A
Recruiting NCT04709705 - DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS) Phase 2/Phase 3
Not yet recruiting NCT05563662 - SURgical Registry of ENDocarditis EuRope
Withdrawn NCT03289104 - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX N/A
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT04199039 - Effects of Endotracheal Tube Fixation Methods on Hemodynamic Parameters During Endotracheal Suction N/A
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Completed NCT02471001 - The Levels of Anaesthetics in Heart Muscle During Heart Surgery N/A
Completed NCT02325726 - RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery. N/A
Completed NCT01246947 - Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation N/A
Completed NCT01151254 - Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation N/A
Completed NCT00821262 - Sevoflurane in Cardiac Surgery Phase 4
Completed NCT00996099 - Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients N/A
Completed NCT00617955 - Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates N/A
Completed NCT00337805 - Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery Phase 2/Phase 3
Completed NCT00336466 - The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS) Phase 2